GSK plc (FRA:GS71)
Germany · Delayed Price · Currency is EUR | Market Cap | 86.80B +24.0% |
| Revenue (ttm) | 38.56B +5.0% |
| Net Income | 5.60B +40.8% |
| EPS | 1.37 +42.6% |
| Shares Out | n/a |
| PE Ratio | 15.50 |
| Forward PE | 9.97 |
| Dividend | 0.78 (3.61%) |
| Ex-Dividend Date | Aug 13, 2026 |
| Volume | 550 |
| Open | 20.80 |
| Previous Close | 20.59 |
| Day's Range | 20.80 - 21.67 |
| 52-Week Range | 16.55 - 26.02 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsNews
GSK plc Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The oncology portfolio has rapidly expanded through focused internal R&D and strategic acquisitions, with key assets like B7-H3, B7-H4, neladalkib, and zidesamtinib driving growth. Robust clinical data and disciplined strategy underpin confidence in meeting ambitious 2031 sales targets.
GSK enters agreement to acquire trispecific TCE from Chimagen
GSK (GSK) announced it has entered an agreement to acquire a trispecific T cell-engager, TCE, from Chimagen Biosciences, a privately held biotechnology company. GSK plans to develop and commercialize ...
GSK upgraded to Buy from Hold at Berenberg
Berenberg analyst Kerry Holford upgraded GSK (GSK) to Buy from Hold with a price target of 2,200 GBp, up from 2,000 GBp. The firm is “increasingly optimistic” about GSK’s growth…
GSK Looks 9.6% Overvalued on GF Value⢠as Dividend Sustainability Remains Key
GSK Looks 9.6% Overvalued on GF Value⢠as Dividend Sustainability Remains Key
GSK strikes up to $750 million deal for cancer-targeting drug
GSK said on Tuesday it had agreed a deal worth up to $750 million to buy a trispecific T cell-engager (TCE), a drug designed to help T-cells target cancer, from China-based biotechnology firm Chimag...
GSK To Buy T Cell-engager For Multiple Myeloma From Chimagen Biosciences For Up To $750 Mln
(RTTNews) - British drug major GSK plc (GSK, GSK.L) announced Tuesday that it has entered an agreement to acquire a potential best-in-class trispecific T cell-engager or TCE for multiple myeloma from ...
GSK PLC (GSK) Shares Surge 4.0% -- What GF Score of 71 Tells Investors
GSK PLC (GSK) Shares Surge 4.0% -- What GF Score of 71 Tells Investors
GSK Shares Jump 3.83% as Twin Lung Cancer Drug Trial Wins Reinforce Its Growing Oncology Pipeline Bet
GSK shares climbed after the company reported encouraging clinical trial results for two lung cancer treatments, strengthening its oncology strategy despite mixed analyst views on the stock.
GSK's Jideytro & Ris-Rez Show Positive Data In Two Lung Cancer Studies
(RTTNews) - GSK plc (GSK), a biopharmaceutical company, reported positive clinical data for two of its lung cancer medicines, with Jideytro showing high response rates in previously untreated ROS1-pos...
Data from Greater Bay Area’s 88 million residents to help improve healthcare policy: GSK
British pharmaceutical company GSK is turning to patient data gathered from the 88 million residents of the Greater Bay Area’s 11 cities to speed up drug development in vaccines and cancer care, as of...
GSK Looks 5.5% Overvalued on GF Value⢠as Dividend Sustainability Remains Key
GSK Looks 5.5% Overvalued on GF Value⢠as Dividend Sustainability Remains Key
GSK presents results from phase I/II ARROS-1 trial evaluating Jideytro
GSK (GSK) announced positive results from the registrational phase I/II ARROS-1 trial evaluating Jideytro in patients with advanced or metastatic ROS1-positive non-small cell lung cancer, NSCLC, who h...
GSK Looks 5.5% Overvalued on GF Value⢠as Dividend Sustainability Remains a Key Focus
GSK Looks 5.5% Overvalued on GF Value⢠as Dividend Sustainability Remains a Key Focus
GSK licensor Hansoh announces ARTEMIS-008 phase III trial met primary endpoint
GSK (GSK) licensor Hansoh Pharmaceutical Group announced positive overall survival, OS, data from ARTEMIS-008, its phase III trial in China evaluating the B7-H3-targeted antibody-drug conjugate, ADC, ...
GSK Targets £1.9B Savings to Fuel Pipeline, Navigate HIV Patent Cliff
GSK NYSE: GSK is accelerating investment in research and development, expanding its late-stage pipeline and targeting cost savings to support product launches while maintaining profitability through u...
GSK Targets £1.9B Savings to Fuel Pipeline, Navigate HIV Patent Cliff
MarketBeat Week in Review – 06/08 - 06/12GSK (NYSE:GSK) is accelerating investment in research and development, expanding its late-stage pipeline and targeting cost savings to support product launches...
GSK to shut vaccine factory in Germany, putting 641 jobs at risk
GSK said on Friday it will be shutting down a vaccine factory in Dresden, Germany, which its website showed produces flu and hepatitis shots, in the summer of 2027.
GSK Looks 6.6% Overvalued on GF Value⢠as Dividend Sustainability Remains Key
GSK Looks 6.6% Overvalued on GF Value⢠as Dividend Sustainability Remains Key
GSK announces Japan’s MHLW approved prefilled syringe presentation of Shingrix
GSK (GSK) announced Japan’s Ministry of Health, Labour and Welfare, MHLW, has approved a prefilled syringe presentation of Shingrix for the prevention of shingles. The vaccine previously came as two…
GSK price target raised to 2,000 GBp from 1,860 GBp at HSBC
HSBC raised the firm’s price target on GSK (GSK) to 2,000 GBp from 1,860 GBp and keeps a Hold rating on the shares. The firm adjusted targets in the healthcare…
Hong Kong targets biomedicine powerhouse status in debut five-year plan
Biomedicine is set to feature in Hong Kong’s first five-year plan, due to be unveiled next week, as the city’s top officials signal closer medical cooperation across the Greater Bay Area. Lending weig...
GSK plc Transcript: Bernstein’s 23rd Annual Pan-European Strategic Decisions Conference
Leadership is accelerating R&D and simplifying operations, driving GBP 2 billion in savings to fund a robust pipeline, including HIV long-acting injectables, oncology, and liver disease innovations. Commercial execution and specialty focus support margin stability through key patent expiries.
GSK initiated with a Sector Perform at RBC Capital
RBC Capital analyst Trung Huynh initiated coverage of GSK (GSK) with a Sector Perform rating and 1,975 GBp price target The shares are up 30% over the past year reflecting…
Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense
Drugmakers are getting a boost from strong earnings and M&A. But they're also havens in a rocky market.
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy
HUTCHMED NASDAQ: HCM said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC. The t...